Replikins - Synthetic Vaccines

The biochemistry of rapid replication


Home
Overview
Videos
Background
The Science
Contact Us
Replikins Press

	Pioneering the development and rapid production of synthetic vaccines
	Recent News
	Flu Pandemic Warning Company sets up in UK March 23, 2010 - UK Trade & Investments announces that Replikins, LTD's UK subsidiary Bioradar UK has "one of the first reliable systems for accurately predicting the strain of future flu outbreaks together with the severity and duration." Read more Replikins' BioRadar™ Software predicted over a year in advance the global H1N1 outbreak and the earlier H5N1 outbreaks Learn more on Businessweek Learn more on Replikinss press releases

	Recent Press
	Current Severe Outbreaks of Foot and Mouth Disease Predicted by Replikins' BioRadar™ One Year in Advance (June 2009) Replikins TransFoot and Mouth Disease(FMD) Vaccine™ now available. Highest replikin count in FMDV in 52 years found in 2009 LONDON, July 16, 2010 -- BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV™, has been developed and is now available... Read more Both H5N1 Bird Flu and H1N1 Swine Flu Replikin Counts™ Increasing Boston, April 9, 2010 - The most recent BioRadar™ (FluForecast™) analysis of the virus genomes of both H5N1, known for high lethality, and H1N1, known for high infectivity, indicates that the Replikin Counts™ of both strains are rising. Such Count increases in a specific strain have been invariably associated with clinical outbreaks of that strain... Read more Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased Boston, November 27, 2009 - Biotech firm Replikins Ltd., which has analyzed the H1N1 virus' genomic data from the 1918 pandemic through the prediction, outbreak, and progress of the current H1N1 pandemic, today issued its latest biochemical analysis of the virus... Read more

	FluForecast™		Synthetic Vaccines
	The current spread of bird flu has drawn attention to the need for improved public health measures to predict, prevent and counter both natural and man-made emerging epidemic threats. Our FluForecast™ software technology has shown that an increase in Replikin Count™ peptide quantities precedes observed epidemics. In addition, after an epidemic has run its course, there is a decline in Replikin Count™ peptide quantities. Previously, no quantitative virus protein changes were known which correlate with, let alone predict, influenza epidemics such as the current H5N1 Bird Flu, or indicate their cessation. Advance specific warning, made possible by our discovery of a biochemistry of rapid replication, now allows time a) for public health measures to be instituted, and b) for an early start on synthetic vaccine development.		Recent outbreaks of SARS, H5N1 (bird flu) and H1N1 (swine flu) have increased awareness of the need for rapid vaccine development in response to emerging viral threats. Replikins software-driven technology allows for earlier development of vaccine candidates, as well as rapid prototyping and production of the vaccines that emerge from early clinical trials. Replikins are a new class of peptides whose increase in concentration in virus proteins (Replikin Count™ peptide quantities) is associated with rapid replication. Subtypes of these peptides are consistently present in a wide range of rapidly-replicating viruses, pointing the way towards synthesis of vaccine candidates.

New Videos

International H1N1 Swine Flu Conference The International Swine Flu Conference addressed best practices to prepare for, respond to, and survive a pandemic.
Synthetic flu vaccine option? Possibility to create a H1N1 synthetic flu vaccine. CNN's Dr. Sanjay Gupta reports.
ABC Boston discusses Bogoch Replikins ABC Boston discusses Replikins synthetic peptide H1N1 vaccine, produced in 7 days, is available now for testing worldwide.